513. A Simple Method To Ensure Titer Conservation of AAV2 Vector Preparations Delivered with Stainless Steel Needles

@inproceedings{Ketchum2006513AS,
  title={513. A Simple Method To Ensure Titer Conservation of AAV2 Vector Preparations Delivered with Stainless Steel Needles},
  author={Elias T. Ketchum and Kevin Kwok and Anthony Ramirez and Junshan Hao and Brian R. Kruegel and Dominick A. Vacante and Raymond T. Bartus and Mehdi Gasmi},
  year={2006}
}
Ceregene is developing AAV2-based gene therapy vectors encoding nerve growth factor (NGF) (CERE-110) and neurturin (NTN) (CERE-120) for the treatment of Alzheimer's and Parkinson's diseases respectively. Targeted delivery of therapeutic vectors to the central nervous system for these applications requires the use of low volumes, low vector titers, and especially low flow rates. Under these conditions, interactions between the delivery hardware materials and the vector particles in suspension… CONTINUE READING